Computational ranking identifies Plexin-B2 in circulating tumor cell clustering with monocytes in breast cancer metastasis

E Emma Schuster N Nurmaa K. Dashzeveg F Fangjia Tong Y Yuzhi Jia L Lamiaa El-Shennawy T Tong Zhang A Andrew D. Hoffman R Reta Birhanu Kitata G Golam Kibria Y Youbin Zhang J Joshua R. Squires C Chunlei Zheng E Erika Ramos R Rokana Taftaf D David Scholten H Hannah F. Almubarak V Valery Adorno-Cruz D David P. Sullivan (Department of Pathology, Northwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine) C Carolina Reduzzi A Allegra C. Minor W William Purev-Ochir S Sabina Spahija R Rong Xu K Kalliopi P. Siziopikou L Leonidas C. Platanias A Ami Shah W William A. Muller W William J. Gradishar M Massimo Cristofanilli (Weill-Cornell Medicine, New York–Presbyterian Hospital, New York) C Chia-Feng Tsai T Tujin Shi H Huiping Liu

Abstract

Abstract Multicellular circulating tumor cell (CTC) clusters can be up to 50 times more efficient than single CTCs in mediating viable metastasis. Here, combining computational ranking and functional determination, we identify the transmembrane protein Plexin-B2 (PLXNB2) as one of the top molecular targets associated with unfavorable distant metastasis-free survival, showing enriched expression in CTC clusters versus single CTCs from patients with advanced breast cancer (mostly female). Loss of PLXNB2 (Plxnb2) reduces the formation of homotypic tumor cell clusters and heterotypic tumor-myeloid cell clusters, reducing spontaneous metastases in female mice bearing human (mouse) breast cancer. Interactions of PLXNB2 with its ligands SEMA4C on tumor cells and SEMA4A on myeloid cells (monocytes) promote homotypic and heterotypic CTC cluster formation, respectively, thereby driving lung metastasis. Global proteomic analysis reveals downstream effectors of the PLXNB2 pathway associated with tumor cell clustering. Thus, PLXNB2 is a therapeutic target for preventing new metastasis in breast cancer.

Article Details

Volume / Issue Vol. 16, Issue 1
Published August 16, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (32)

E

Emma Schuster

N

Nurmaa K. Dashzeveg

F

Fangjia Tong

Y

Yuzhi Jia

L

Lamiaa El-Shennawy

T

Tong Zhang

A

Andrew D. Hoffman

R

Reta Birhanu Kitata

G

Golam Kibria

Y

Youbin Zhang

J

Joshua R. Squires

C

Chunlei Zheng

E

Erika Ramos

R

Rokana Taftaf

D

David Scholten

H

Hannah F. Almubarak

V

Valery Adorno-Cruz

D

David P. Sullivan

Department of Pathology, Northwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine

C

Carolina Reduzzi

A

Allegra C. Minor

W

William Purev-Ochir

S

Sabina Spahija

R

Rong Xu

K

Kalliopi P. Siziopikou

L

Leonidas C. Platanias

A

Ami Shah

W

William A. Muller

W

William J. Gradishar

M

Massimo Cristofanilli

Weill-Cornell Medicine, New York–Presbyterian Hospital, New York

C

Chia-Feng Tsai

T

Tujin Shi

H

Huiping Liu